Skip to content

Development and Application Research of Diabetes Nephropathy Diagnostic Technology Based on Urinary Extracellular Vesicles

Development and Application Research of Diabetes Nephropathy Diagnostic Technology Based on Urinary Extracellular Vesicles

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101615
Enrollment
Unknown
Registered
2025-04-27
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy (DN)

Interventions

Gold Standard:Pathological examination based on renal biopsy
Index test:Urinary Extracellular Vesicle Testing

Sponsors

Jiangsu Provincial Government Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) **Age 18-75 years.** 2) **Meeting WHO 2023 diagnostic criteria for diabetes:** - Fasting plasma glucose >= 7.0 mmol/L, **or** - 2-hour postprandial glucose >= 11.1 mmol/L, **or** - HbA1c >= 6.5%. 3) **Diagnosed with diabetic kidney disease (DKD), defined as:** - Persistent proteinuria (urinary albumin-to-creatinine ratio [UACR] >= 30 mg/g), **or** - Estimated glomerular filtration rate (eGFR) = 10 years.** 5) **Voluntarily signed informed consent, with ability to understand and comply with study procedures.** 6) **Stable blood pressure control (systolic = 90 g/L, platelets >= 100×10?/L. - **Liver function:** ALT/AST <= 2.5× upper limit of normal (ULN). - **Serum potassium:** 3.5-5.5 mmol/L.

Exclusion criteria

Exclusion criteria: 1) **Non-diabetic kidney disease** (e.g., glomerulonephritis, polycystic kidney disease). 2) **Severe cardiovascular comorbidities** (e.g., recent myocardial infarction, unstable angina). 3) **Participation in other clinical trials within the past 6 months.** 4) **Active severe infections or liver disease** (e.g., active hepatitis B or C). 5) **Pregnant or lactating women.** 6) **Laboratory abnormalities:** - eGFR 5.5 mmol/L. 7) **Other conditions deemed ineligible by investigators** (e.g., poor compliance, life expectancy < 6 months).

Design outcomes

Primary

MeasureTime frame
Urinary Extracellular Vesicle;Accuracy;Sensitivity;Specificity;

Countries

China

Contacts

Public ContactShuang Qu

Jiangsu Provincial Government Hospital

qushuang160828@163.com+86 151 9596 2208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026